Hemophilia Pipeline Summary

DelveInsight’s, “Hemophilia - Pipeline Insight, 2026” report provides comprehensive insights about 52+ companies and 55+ pipeline drugs in Hemophilia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hemophilia: Understanding

Hemophilia: Overview

Hemophilia, is the most common severe hereditary hemorrhagic disorder. Both hemophilia A and B result from factor VIII and factor IX protein deficiency or dysfunction, respectively, and are characterized by prolonged and excessive bleeding after minor trauma or sometimes even spontaneously. There is hemophilia C as well, which occurs due to deficiency of clotting factor XI but is rare. Hemophilia is usually an inherited condition and is caused by the deficiency of clotting factors in the blood. The encoding genes for factors VIII and factor IX are present in the long arm of chromosome X.

Hemophilia is a genetic bleeding disorder caused by a deficiency of clotting factors, which leads to impaired blood clotting and prolonged bleeding. Individuals with hemophilia may experience spontaneous or excessive bleeding after injuries, medical procedures, or minor trauma. Repeated bleeding episodes, particularly in joints and muscles, can result in pain, swelling, and long-term complications if untreated. Major Symptoms include Joint bleeding, swelling, Easy bruising or muscle hematomas and frequent or prolonged bleeding episodes.

Hemophilia is caused by a deficiency or dysfunction of clotting factor VIII (Hemophilia A) or factor IX (Hemophilia B), which play essential roles in the intrinsic pathway of the coagulation cascade. Normally, the intrinsic and extrinsic pathways activate factor X, leading to the formation of thrombin and conversion of fibrinogen into fibrin to form a stable blood clot. In hemophilia, the lack of factor VIII or IX disrupts the intrinsic pathway, reducing thrombin generation and impairing fibrin clot formation. As a result, blood clotting becomes ineffective, leading to prolonged bleeding and recurrent hemorrhages, particularly in joints and muscles.

The management of hemophilia primarily focuses on preventing bleeding episodes and effectively controlling acute bleeds when they occur. Treatment options include clotting factor replacement therapy, involving infusion of factor VIII for Hemophilia A or factor IX for Hemophilia B to restore deficient clotting factors; desmopressin (DDAVP), which is mainly used in mild Hemophilia A to temporarily increase factor VIII levels; antifibrinolytic agents, such as tranexamic acid and aminocaproic acid, that help stabilize blood clots and reduce excessive bleeding; and gene therapy, which aims to provide long-term or potentially curative treatment by introducing a functional clotting factor gene to enable sustained production of the deficient clotting factor.

"Hemophilia- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hemophilia pipeline landscape is provided which includes the disease overview and Hemophilia treatment guidelines. The assessment part of the report embraces, in depth Hemophilia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hemophilia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Hemophilia R&D. The therapies under development are focused on novel approaches to treat/improve Hemophilia.

Hemophilia Emerging Drugs Chapters

This segment of the Hemophilia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hemophilia Emerging Drugs

• NXT007: Hoffmann-La Roche

NXT007 is a next-generation investigational bispecific antibody, being investigated as a prophylactic (preventive) treatment option for people with haemophilia NXT007 was engineered by Chugai – a member of the Roche Group with the aim of optimising factor VIII-mimetic activity and half-life, to further enhance potency, efficacy, dosing and administration convenience. This drug brings together factor IXa and factor X proteins required to activate the natural coagulation cascade. NXT007 is being studied in a robust clinical development programme exploring its potential to achieve sustained elevated bleed protection to people who do not have haemophilia A.Currently, the drug is in the Phase III stage of its development for the treatment of Hemophilia A.

• GS1191: Gritgen Therapeutics

GS1191 (GS1191-0445) is an investigational AAV8-based gene therapy being developed for the treatment of Hemophilia A. The therapy is designed to deliver a B-domain-deleted human factor VIII (FVIII) gene to hepatocytes through a single intravenous infusion. Under the control of a human liver-specific promoter, the transferred gene enables sustained expression and secretion of FVIII into the bloodstream, with the goal of restoring coagulation factor activity and providing long-term bleed control following a one-time treatment. Currently, the drug is in the Phase III stage of its development for the treatment of Hemophilia A.

• REGV131-LNP1265: Regeneron Pharmaceuticals /Intellia Therapeutics

REGV131-LNP1265 is an experimental, in-vivo CRISPR/Cas9-based gene insertion therapy which aims to provide a potential long-term, one-time treatment by enabling liver cells to produce functional coagulation Factor IX, eliminating the need for regular replacement therapies. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Hemophilia B.

Further product details are provided in the report……..

Hemophilia: Therapeutic Assessment

This segment of the report provides insights about the different Hemophilia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Hemophilia

There are approx. 52+ key companies which are developing the therapies Hemophilia. The companies which have their Hemophilia drug candidates in the most advanced stage, i.e. Phase III include, Hoffmann-La Roche, and others.

• Phases

DelveInsight’s report covers around 55+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Hemophilia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hemophilia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hemophilia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hemophilia drugs.

Hemophilia Report Insights

• Hemophilia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hemophilia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hemophilia drugs?
• How many Hemophilia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hemophilia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hemophilia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hemophilia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Hoffmann-La Roche
• Gritgen Therapeutics
• Regeneron Pharmaceuticals
• Intellia Therapeutics
• Staidson (Beijing) BioPharmaceutical
• Suzhou Alphamab
• Equilibra Bioscience
• Metagenomi Therapeutics
• ASC Therapeutics
• Biocad

Key Products

• NXT007
• GS1191
• REGV131-LNP1265
• STSP 0601
• KN057
• SR604
• MGX001
• SPK-8011QQ
• ASC 618
• ANB-002
• RG6512